Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate)
Lymphoid System Disorder
Explore 4 assets in Lymphoid System Disorder →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Geron Corporation
Modality
nucleic_acid
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00124189CT.gov Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoid System Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate) (this asset) | Geron Corporation | P1 | CC · 47 |
| il-15 enhanced engineered nk cells | M.D. Anderson Cancer Center | P1 | CC |
| Cyclophosphamide | M.D. Anderson Cancer Center | P1 | CC |
| Tgfbr2 Ko Car27/Il-15 Nk Cells | M.D. Anderson Cancer Center | P1 | CC |
| Fludarabine | M.D. Anderson Cancer Center | P1 | CC |
Other indications for Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P2 | B · 57 |
| Plasma Cell Myeloma | — | P2 | CCC · 53 |
| Hepatoblastoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate) in Lymphoid System Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dna-d3-amino-3-deoxy-p-thiot-a-g-g-g-t-t-a-g-a-c-a-a-5-o-2-hydroxy-3-1-oxohexadecylaminopropyl-hydrogen-phosphorothioate-lymphoid-system-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →